| Literature DB >> 35866234 |
Md Rayhan Mahmud1, Sharmin Akter2, Sanjida Khanam Tamanna2, Lincon Mazumder2, Israt Zahan Esti2, Sanchita Banerjee2, Sumona Akter2, Md Rakibul Hasan2, Mrityunjoy Acharjee3, Md Sajjad Hossain4, Anna Maria Pirttilä5.
Abstract
The human intestine hosts diverse microbial communities that play a significant role in maintaining gut-skin homeostasis. When the relationship between gut microbiome and the immune system is impaired, subsequent effects can be triggered on the skin, potentially promoting the development of skin diseases. The mechanisms through which the gut microbiome affects skin health are still unclear. Enhancing our understanding on the connection between skin and gut microbiome is needed to find novel ways to treat human skin disorders. In this review, we systematically evaluate current data regarding microbial ecology of healthy skin and gut, diet, pre- and probiotics, and antibiotics, on gut microbiome and their effects on skin health. We discuss potential mechanisms of the gut-skin axis and the link between the gut and skin-associated diseases, such as psoriasis, atopic dermatitis, acne vulgaris, rosacea, alopecia areata, and hidradenitis suppurativa. This review will increase our understanding of the impacts of gut microbiome on skin conditions to aid in finding new medications for skin-associated diseases.Entities:
Keywords: Gut microbiome; dietary components; gastrointestinal health; gut dysbiosis; prebiotics; probiotics; skin disease; skin-gut axis
Mesh:
Substances:
Year: 2022 PMID: 35866234 PMCID: PMC9311318 DOI: 10.1080/19490976.2022.2096995
Source DB: PubMed Journal: Gut Microbes ISSN: 1949-0976
Figure 1.Prisma flowchart. This diagram represents the Prisma flowchart and demonstrates database searching, screening, excluding, retrieval, and eligibility findings for the final full-text studies used in this review. This illustration is based on[17] and created with BioRender.com (2022).
Figure 2.Microbial composition of gut and skin. Skin, the largest organ of the human body, shelters numerous commensal microbes (bacteria, fungi and viruses) and prevents entry by foreign pathogens by acting as a physical barrier. Skin can be broadly categorized as sebaceous or oily (glabella), moist (antecubital fossa) or dry (volar forearm), according to the physiological characteristics of each skin site. Specific microbial groups dominate different skin sites. Like skin, human gut is a home to innumerable amounts of microbes. A number of gut bacteria (e.g, Lactobacilli, E. coli, Bifidobacterium, Streptococcus thermophilus) contribute to maintenance of human health state, whereas others (e.g., Clostridium difficile, Campylobacter, Enterococcus faecalis, Helicobacter pylori) are more prevalent in disease states. The illustration was adapted from “Immune Organs in the Human Body”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates, associated information based on .[25–27,28]
Figure 3.Gut-Skin communication through immuno-cross-linking. This illustration represents the immunological crosstalk between the gut and skin. (A) CX3CR1+ DCs generate dendrites for phagocytosis at homeostatic condition, whereas CD103+ DCs relocate to Peyer’s patches or mesenteric lymph nodes to deliver antigens to naive T lymphocytes. DC secretes interleukin (IL)-12, IL-15, and interferon (IFN) in response to commensal activation to stimulate conventional NK (cNK) cells. (B) As metabolic by-products, short-chain fatty acids (SCFAs) upregulate H3K4me3 in DC and enhance the production of IL-6, IL-12, IFN, and tumor necrosis factor (TNF), which is an alternative way to train cNK cells. Trained cNK cells have the necessary cytotoxicity and cytokine production capacity to fight bacteria and viruses. (C) MAIT cells can be directly stimulated to create IFN-γ by IL-12 or IL-15 in combination with IL-18 produced by APCs in response to TLR ligands. (D) TNF-like protein, a gut-associated pro-inflammatory cytokine, activates MAIT cells when coupled with IL-12 and IL-18. Phagocytes help the body defend itself by phagocytosing and producing cytokines like IL-6 and IL-23. (E) Foxp3+ Treg cells and Tfh/ex-Th17 cells cluster in Peyer’s patches, promoting B cell class switching and secretory (s)IgA production. These help to compartmentalize the commensal microbiome and modulate the diversity of the homeostatic microbiome. (F) ILC2 is activated by IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) produced by intestinal epithelial cells (IEC) in response to commensal bacteria. (G) ILC3 expressing MHC II is capable of delivering commensal antigens to CD4 + T cells, reducing their self-reactivity. (H) In an ID2-dependent manner, microbial signals are also used to prime ILC3. ILC3, which has been primed secretes IL-22 and participates in the pathogen defense by stimulating the synthesis of antimicrobial peptides, such as REGIIIβ and REGIIIγ. This illustration was based on [55–58] and created in BioRender.com (2022).
Figure 4.Mechanisms of the interaction at the gut-skin axis. This illustration represents the underlying mechanisms of gut-skin interaction. Various dietary components, illnesses, lifestyles, prebiotics, antibiotics, probiotics, and novel biological drugs can alter gut microbial communities. A. The alteration can lead to dysbiosis, which can further (i) decrease the gut mucus layer, (ii) results in the passage of microbes through the intestinal barrier, (iii) cause the production of toxic products, (iv) induce harmful effects by neurotransmitters of the gut microbes or the host, (v) produce B cell hyperresponsiveness, (vi) impair T cell differentiation, (vii) create low levels of IgA secretion. B. Dysbiotic gut microbes, toxic products, neurotransmitters, and altered immune cells pass through the circulatory system turning the skin condition from healthy (left) to dysbiotic (right). (i) Healthy skin possesses a balanced composition of microbes and proper quantities of human and microbial AMPs. (ii) A dysbiotic skin condition is induced by the pathogen due to improper immune system functioning and low quantities of human and microbial AMPs. C. Dysbiotic skin microbes trigger skin inflammation and can be involved in the onset of a variety of skin illnesses. This illustration is based on [15]and [16]and created with BioRender.com (2022).
Microbial species and metabolites from the gut that have been associated with skin effects.
| Organism | Effects on skin | Mechanism | References | ||
|---|---|---|---|---|---|
| Protection against psoriasis | Prevention of colonization of pathogenic flora on skin by competitive inhibition and the SCFAs production | [ | |||
| Rosacea-related signs and symptoms | Production of cytotoxin and by proliferating the production of reactive oxygen species-nitric oxide [NO], which causes gut mucosal inflammation and changes physiological processes in the skin including vasodilation, inflammation and immunomodulation. | [ | |||
| Chronic atopic dermatitis progression resulting in gut epithelial barrier impairment | Dysregulation of gut epithelial inflammation | [ | |||
| Decrease skin inflammation | Alteration of the number of cytotoxic CD8 + T cells | [ | |||
| Reduce the size of acne lesions as well as inflammation | Inhibition of mast cell degranulation, TNF-α release, edema and vasodilation, and thereby speeding up the restoration of barrier function | [ | |||
| Reduce the scratching behavior in atopic dermatitis | Increase of levels of the kynurenic acid metabolite | [ | |||
| Alleviate the allergic symptoms of atopic dermatitis as well as Crohn’s disease like other chronic inflammatory diseases | Anti-inflammatory action | [ | |||
| Larger number of | Onset of atopic dermatitis symptoms in childhood | Immune dysregulation as a result of decreased Treg cell inducing beneficial bacteria | [ | ||
| Decrease in Firmicutes and increase in Bacteroides | Development of acne vulgaris | Dysbiosis by altering the serological cytokine levels promoting inflammation | [ | ||
| Metabolites | Effects on skin | Mechanism | References | ||
| SCFAs | Increase the epithelial barrier function and skin-inflammation | Development of Tregs within the colon, DCs | [ | ||
| GABA | Itch restriction | Inhibition of neurons which are responsible for itch-signaling in the spinal cord | [ | ||
| Tryptophan | Regulate skin inflammation | Activation of AhR and inhibition of TSLP production in keratinocytes | [ | ||
| Dopamine | Inhibition of hair growth | Through the stimulation of catagen induction | [ | ||
| Serotonin | Involved in skin pigmentation | Modulation of melatonin | [ | ||
| Acetylcholine | Barrier function | Not reported | [ | ||
| Phenol & p-cresol | Impaired epidermal barrier function | Skin hydration reduction and disruption of keratinization | [ | ||
| Propionic acid | Promote skin homeostasis by reducing inflammation | Antimicrobial effects | [ | ||
| Sodium butyrate | Treat psoriasis and other hyperproliferative skin diseases | Modulation of several key cellular processes including differentiation, proliferation, and apoptosis. | [ | ||
| Galactoligosaccharides | Reduction of infant eczema and allergy | Through the stimulation of Tregs | [ | ||
| Polysaccharide A and retinoic acid | Suppress inflammation | Induction of accumulation of Tregs | [ | ||
| Saturated | Development of acne | Impairment in nutrient signaling. SREBP-1 overexpression and increased sebum synthesis of fatty acids (e.g., free oleic acid) and triglycerides which promotes flourishing. | [ | ||
| High-peptides and unsaturated omega-3 fatty acids | Act against hypersensitivity (allergies) and asthma | Through the development of Tregs | [ | ||
| High-fat and alcohol | Promote skin inflammation and oxidative | Increase of pro-inflammatory cytokines secretion | [ | ||
Human clinical studies that have used gut microbial interventions for human skin diseases.
| Participants | Intervention | Key findings | References |
|---|---|---|---|
| 43 children (aged 4–17 years) | Reducing the severity of AD according to the SCORAD index | [ | |
| 50 children (aged 4 to 17 years) | Reducing the severity of AD according to the SCORAD index | [ | |
| 31 patients (aged 18–75 years) | Reducing the severity of AD according to the SCORAD index | [ | |
| 20 Caucasian adult | Reducing the acne severity | [ | |
| 101 Japanese female students (aged 18–23 years) | Enhancing stool consistency, defecation frequency, and feces quantity to maintain healthy skin | [ | |
| 110 volunteers (aged 41 and 59 years) | Enhancing skin hydration, reduction of wrinkle depth, and overall skin shine and elasticity | [ | |
| 166 pregnant women | Reducing the risk of newborns eczema | [ | |
| 45 females (aged 18 to 35 years) | Improving the total lesion for acne patients | [ | |
| 26 male and female (aged 18–60 years) | Improving the CRP levels in psoriasis patients | [ | |
| 30 women (aged 30–48 years) | Improving hair follicles and skin hydration | [ | |
| A woman (aged 47 years) | Reducing the risk of psoriasis | [ | |
| 20 children (aged 4–15 years) | Effective as Serum Markers of Atopic Dermatitis in Children | [ | |
| 56 Patients (aged 18 to 30 years) | Reducing the severity of acne vulgaris by selectively lowering TGs in skin surface lipids. | [ | |
| 66 female volunteers (aged 35–45 years) | Improving skin hydration and physical aggression | [ | |
| 70 patients (12 years of age or older) | Improving the severity of acne | [ | |
| 474 patients | Reducing the risk of eczema | [ | |
| 59 patients | Reducing the severity of AD according to the SCORAD index | [ | |
| 56 children (aged 6–18 months) | Reducing the severity of AD according to the SCORAD index | [ | |
| 41 children (aged 1–13 years) | Reducing the severity of atopic eczema | [ | |
| 159 pregnant | Reducing the severity of atopic eczema | [ | |
| 159 patients | Reducing the severity of atopic eczema in children | [ | |
| 27 infants | Reducing the severity of atopic eczema | [ |